Consolidated Statements of Operations - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
| Revenues: |
|
|
|
| Total revenues |
$ 11,838
|
$ 5,885
|
$ 3,364
|
| Cost of revenues |
10,564
|
5,981
|
3,304
|
| Gross profit/(loss) |
1,274
|
(96)
|
60
|
| Operating expenses: |
|
|
|
| Sales and marketing |
37,575
|
16,077
|
6,303
|
| Research and development |
16,261
|
5,293
|
2,497
|
| General and administrative |
24,836
|
13,823
|
8,865
|
| Total operating expenses |
78,672
|
35,193
|
17,665
|
| Loss from operations |
(77,398)
|
(35,289)
|
(17,605)
|
| Other income/(expense): |
|
|
|
| Interest income, net |
151
|
40
|
(2,657)
|
| Change in fair value of warrant liability |
(1,088)
|
(1,228)
|
(441)
|
| Gain on debt extinguishment of convertible notes |
|
|
928
|
| Change in fair value of derivative liability |
|
|
(355)
|
| Total other expense |
(937)
|
(1,188)
|
(2,525)
|
| Net loss |
$ (78,335)
|
$ (36,477)
|
$ (20,130)
|
| Weighted average shares outstanding used in computing net loss per share, basic and diluted |
28,884,874
|
16,979,411
|
7,005,037
|
| Net loss per share of common stock outstanding, basic and diluted |
$ (2.71)
|
$ (2.15)
|
$ (2.87)
|
| Assay Revenue |
|
|
|
| Revenues: |
|
|
|
| Total revenues |
$ 11,023
|
$ 4,241
|
$ 1,403
|
| Contract Revenue |
|
|
|
| Revenues: |
|
|
|
| Total revenues |
$ 815
|
$ 1,644
|
$ 1,961
|